HARROW, INC.

Harrow Closes Acquisition of TYRVAYA®

Harrow closed its acquisition of TYRVAYA (varenicline solution) nasal spray from Viatris, gaining worldwide rights excluding Japan. Harrow paid $30 million in cash at closing, funded with cash on hand, and may owe up to $70 million in sales-tied milestones for a potential total of $100 million. TYRVAYA is the only FDA-approved nasal spray for dry eye disease and complements Harrow's flagship DED product VEVYE; roughly 40 Viatris commercial personnel are expected to join Harrow in Q4 2026. Management expects TYRVAYA to contribute more than $30 million of revenue in 2027.

•27d ago

Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections

Harrow reported positive results from a 50-patient study showing its IHEEZO anesthetic gel reduced patient-reported discomfort by 58% compared to proparacaine during intravitreal injections. The contralateral-eye study demonstrated statistically significant differences favoring IHEEZO at all four post-injection assessments, with the largest benefits occurring immediately after the procedure. Management believes the data strengthens physician confidence in IHEEZO and supports broader utilization across high-volume retina practices.

•2mo ago

Harrow Announces Second Quarter 2026 Financial Results

Harrow reported Q2 2026 revenue of $70.7 million, representing a 60% sequential increase and 11% year-over-year growth, while reaffirming full-year guidance for revenue of $350 million to $365 million. The company announced the pending acquisition of TYRVAYA, expected to close in H2 2026 and contribute over $30 million in revenue by 2027, alongside the successful July launch of the BYOOVIZ biosimilar. Commercial execution drove record demand across key portfolios, with VEVYE revenue up 40% sequentially to $29.4 million and IHEEZO unit demand increasing 44% sequentially despite reimbursement headwinds.

•2mo ago

Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

Harrow has entered into a definitive agreement to acquire the global rights to TYRVAYA nasal spray from Viatris Inc. for $30 million in cash at closing and up to $70 million in potential milestone payments. The acquisition complements Harrow's flagship VEVYE franchise by adding a nasal spray treatment for dry eye disease, creating a broader portfolio of differentiated options for patients. The transaction is expected to close in the second half of 2026, funded by cash on hand, and is anticipated to be financially accretive shortly after closing.

•2mo ago

Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026

Samsung Bioepis and Harrow presented interim Phase 4 post-marketing surveillance data for SB11 (BYOOVIZ) at the ASRS 2026 meeting. In the study of 298 patients, SB11 showed a safety profile comparable to reference ranibizumab, with statistically significant improvements in BCVA and CST for treatment-naïve patients. Patients switching from other anti-VEGF therapies maintained efficacy, reinforcing confidence in the biosimilar’s clinical profile.

•3mo ago

Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting

Harrow presented positive clinical data for IHEEZO and BYOOVIZ at the ASRS 2026 Annual Meeting, including interim results showing reduced pain trends for IHEEZO and real-world evidence of no increased infection risk across 20,000 injections. The company is actively enrolling the 236-patient QUELL trial with topline data expected in Q4 2026, while partner Samsung Bioepis shared interim findings from a BYOOVIZ post-marketing surveillance study. Management stated that this expanding body of evidence strengthens the commercial foundation for its growing retina portfolio and supports long-term physician adoption.

•3mo ago

Harrow Announces Commercial Launch of BYOOVIZ® in the United States

Harrow announced the U.S. commercial launch of BYOOVIZ, the first FDA-approved ophthalmology biosimilar referencing LUCENTIS, developed in partnership with Samsung Bioepis. The product enters an estimated $9 billion U.S. anti-VEGF market, leveraging exclusive commercialization rights that also cover the upcoming OPUVIZ biosimilar. This launch expands Harrow's retina franchise, joining existing products IHEEZO and TRIESENCE, and is supported by the company's specialized commercial infrastructure.

•4mo ago

Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow

Samsung Bioepis announced the US relaunch of BYOOVIZ, the first interchangeable ophthalmology biosimilar to Lucentis, in partnership with Harrow. Harrow assumes full commercialization responsibilities for BYOOVIZ and OPUVIZ in the US, following the transition of rights from Biogen at the end of 2025. Under the partnership, Samsung Bioepis handles development and manufacturing while Harrow leverages its commercial network to target the anti-VEGF therapy market.

•4mo ago

Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare

Harrow has re-launched VERKAZIA, its FDA-approved cyclosporine ophthalmic emulsion, for the treatment of vernal keratoconjunctivitis (VKC) in children and adults. The company is deploying a comprehensive commercial strategy focused on physician education, patient access, and affordability to ensure dependable supply and remove access barriers. VERKAZIA is positioned as a steroid-sparing therapy, addressing a significant unmet need in pediatric eyecare where 61% of patients are inadequately controlled on antihistamines alone.

•4mo ago